The effect of competitive antagonist chain length on NMDA receptor subunit selectivity

被引:47
作者
Feng, BH
Morley, RM
Jane, DE
Monaghan, DT
机构
[1] Univ Nebraska, Med Ctr, Dept Pharmacol, Omaha, NE 68198 USA
[2] Univ Bristol, Dept Pharmacol, Bristol BS8 1TD, Avon, England
关键词
NMDA; glutamate; Xenopus oocyles; NR2; antagonist; CPP;
D O I
10.1016/j.neuropharm.2004.11.004
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The widely-used N-methyl-D-aspartate (NMDA) receptor antagonists (R)-4-(3-phosphonopropyl) piperazine-2-carboxylic acid ((R)-CPP) and (R)-2-amino-7-phosphonoheptanoate ((R)-AP7) are frequently used as general NMDA receptor antagonists and assumed not to display significant selectivity among NMDA receptor NR2 subunits. However, electrophysiotogical studies have suggested that certain longer chain N-methyl-D-aspartate (NMDA) receptor competitive antagonists, such as (R)-CPP are ineffective at subpopulations of NMDA receptors in the red nucleus, superior colliculus, and hippocainpus. Using recombinant receptors expressed in Xenopus oocytes, we have examined the effect of antagonist chain length on NR2 subunit selectivity. All antagonists displayed the potency order (high to low affinity) of NR2A > NR2B > NR2C > NR2D, however the longer chain antagonists (having 7 instead of 5 bond lengths between acidic groups) displayed much greater subunit selectivity than their short-chain homologues. For example (R)-CPP displayed a 50-fold difference in affinity between NR2A-containing and NR2D-containing NMDA receptors, while the shorter chain hornologue 4-(phosphonomethyl) piperazine-2-carboxylic acid (PMPA) displayed only a 5-fold variation in affinity. These results can account for the earlier physiological findings and suggest that longer chain antagonists such as (R)-CPP and (R)-AP7 should not be used as general NMDA receptor antagonists. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:354 / 359
页数:6
相关论文
共 26 条
[1]  
ANDALORO VJ, 1996, PHARM NMDA RECEPTOR
[2]   5-phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition [J].
Auberson, YP ;
Allgeier, H ;
Bischoff, S ;
Lingenhoehl, K ;
Moretti, R ;
Schmutz, M .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (07) :1099-1102
[3]   Visual experience alters the molecular profile of NMDA-receptor-mediated sensory transmission [J].
Binns, KE ;
Turner, JP ;
Salt, TE .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1999, 11 (03) :1101-1104
[4]  
Brickley SG, 2003, J NEUROSCI, V23, P4958
[5]  
BULLER AL, 1994, J NEUROSCI, V14, P5471
[6]   Pharmacological heterogeneity of NMDA receptors: Characterization of NR1a/NR2D heteromers expressed in Xenopus oocytes [J].
Buller, AL ;
Monaghan, DT .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 320 (01) :87-94
[7]   The NMDA receptor NR2B subunit: A valid therapeutic target for multiple CNS pathologies [J].
Chazot, PL .
CURRENT MEDICINAL CHEMISTRY, 2004, 11 (03) :389-396
[8]  
Christie JM, 2000, J PHARMACOL EXP THER, V292, P1169
[9]   Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid [J].
Feng, BH ;
Tse, HW ;
Skifter, DA ;
Morley, R ;
Jane, DE ;
Monaghan, DT .
BRITISH JOURNAL OF PHARMACOLOGY, 2004, 141 (03) :508-516
[10]   CORTICALLY EVOKED EXCITATORY SYNAPTIC TRANSMISSION IN THE CAT RED NUCLEUS IS ANTAGONIZED BY D-AP5 BUT NOT BY D-AP7 [J].
HARRIS, NC ;
DAVIES, J .
BRAIN RESEARCH, 1992, 594 (01) :176-180